Linda Huang, MD
Glaucoma Specialist · Rochelle Park, NJNPI 1437441979
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,967 of the $49,681 with a category attached, or 62.3%. Aerie Pharmaceuticals, Inc. accounts for 60.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $18,460 and has fallen 94.7% since, to $977 in 2025.
Across 204 payments — averaging $243.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$30K
- Glaukos Corporation$11K
- Alcon$3K
- Sight Sciences, Inc.$3K
- AbbVie$1K
- NEW World Medical,inc.$266
- plus $427 from 10 others
What the payments were for
- Consulting fees$9,47519%
- Speaking & faculty fees$30,96762%
- Travel & lodging$3,4817%
- Food & beverage$5,52011%
- Education$1930%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 54 | $29,898 |
| Glaukos Corporation | 17 | $11,422 |
| Alcon | 18 | $3,275 |
| Sight Sciences, Inc. | 10 | $2,964 |
| AbbVie(2 entities) | 75 | $1,429 |
| NEW World Medical,inc. | 3 | $266 |
| Bausch & Lomb Americas Inc. | 8 | $120 |
| Sun Pharmaceutical Industries Inc. | 4 | $70 |
| Oyster Point Pharma, Inc. | 4 | $65 |
| Novartis | 4 | $52 |
| Tepha Inc | 1 | $33 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $28 |
| Amgen | 1 | $17 |
| GSK | 1 | $15 |
| Biotissue Holdings Inc. | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$32,355
- Rhopressa$27,683
- OMNI$2,738
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$2,300
- iStent inject W$1,658
- iStent inject Trabecular Micro-Bypass Stent System$1,152
- DURYSTA$356
- iDose$182
- KXL System$158
- Photrexa$158
- iDoseTR$152
- iStent Trabecular Micro-Bypass System Model iS3$143
- Hydrus Microstent$124
- OMNI(R) SURGICAL SYSTEM (US)$120
- SION SURGICAL INSTRUMENT$120
- LUMIGAN$106
How this compares
Too few glaucoma specialist providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 451 | $207,975 |
| LumiganBimatoprost | 409 | $202,115 |
| CombiganBrimonidine Tartrate/Timolol | 229 | $113,055 |
| Alphagan PBrimonidine Tartrate | 265 | $111,132 |
| RocklatanNetarsudil Mesylat/Latanoprost | 146 | $75,539 |
| VyzultaLatanoprostene Bunod | 122 | $60,190 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 124 | $39,768 |
| RestasisCyclosporine | 45 | $35,423 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 177 | $35,121 |
| Brimonidine Tartrate | 698 | $32,446 |
| Pilocarpine Hcl | 499 | $31,290 |
| XiidraLifitegrast | 24 | $29,166 |
| Travoprost | 170 | $28,058 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 130 | $27,174 |
| Timolol MaleateTimolol Maleate/Pf | 40 | $21,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $1,429 | $461,725948 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $29,898 | $283,514597 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $120 | $89,356146 claims |
| AlconSimbrinza, Azopt | $3,275 | $51,416145 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $28 | $14,32347 claims |
| NovartisTravatan Z | $52 | $13,60219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Rochelle Park
- Paul LamaRochelle Park$72K
- Alice WilliamsVineland$8K
- Jessica ScottEast Orange$8K
- Matthew HoslerRahway$7K
- Gregory KramerWestfield$2K
- Sze WongOld Bridge$2K
- Omar Mobin-UddinNew Brunswick$1K
- Miriam HabielNewark$1K
- Khelly SavantClifton$774
- Linda ZhangWarren$610
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.